News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Athersys, Inc. (ATHX) Reports First Quarter 2014 Results


5/9/2014 8:53:27 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CLEVELAND, May 8, 2014 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the three months ended March 31, 2014.

"While we were disappointed by the recent failure of a single administration of MultiStem® cell therapy to demonstrate meaningful benefit at 8 weeks for a challenging patient population with chronic, advanced ulcerative colitis, we are pleased with the favorable safety and tolerability profile observed in this study, as we have seen in other studies that Athersys has conducted," said Dr. Gil Van Bokkelen, Ph.D., Chairman and Chief Executive Officer of Athersys. "We remain confident in the potential for MultiStem in multiple disease areas, including ischemic stroke and other conditions, and believe that we are well positioned to advance these opportunities."

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES